Agonistic CD40 antibodies hold great potentials in the treatment of malignant tumors,yet their efficacy and safety remain to be fully established.This research identified and humanized two high-binding and high-affinity agonistic anti-CD40 monoclonal antibodies(31A2-2 and 42D11-8)via hybridoma technique,and evaluated their pharmacodynamics through the NPG mouse xenograft model.The results revealed that the modified antibodies maintained high binding affinity after measurement,and demonstrated robust activation capacity in dendritic cell activation assays,thereby stimulated dendritic cells to release IL-12.Both antibodies exhibited significant antitumor activities in NPG mice,with tumor growth inhibition rates reaching 86.83％and 87.95％respectively.This study provided data support for the development of agonistic CD40 drugs.
维普
万方数据